SWOG clinical trial number
SWOG-9413

Phase II Treatment with Etoposide (E), Leucovorin (L), 5-Fluorouracil (F) and Interferon Alpha 2b (I), (ELFI) + G-CSF for Locally Advanced or Recurrent Pancreatic Adenocarcinoma

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Phase II Treatment with Etoposide (E), Leucovorin (L), 5-Fluorouracil (F) and Interferon Alpha 2b (I), (ELFI) + G-CSF for Locally Advanced or Recurrent Pancreatic Adenocarcinoma
Activated
05/01/1995
Closed
03/15/1996

Research committees

Gastrointestinal Cancer

Publication Information Expand/Collapse

2014

Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single arm phase II trials

PA Philip;K Chansky;L Rubenstein;M Leblanc;L Seymour;SP Ivy;SR Alberts;PJ Catalano;J Crowley Clinical Cancer Research 20(16):4176-4185;

PMid: PMID24914040 | PMC number: PMC4296727

2000

A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: A Southwest Oncology Group study (SWOG-9413)

JS Macdonald;JL Jacobson;M Modiano;DF Moore Jr;DR Gandara;LE Schroder;RA Chapman Investigational New Drugs 18:269-273

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
76%
Open
Phase